Results of a meta-analysis showed that patients with moderate-to-severe inflammatory bowel disease (IBD) who were able to achieve clinical remission, compared with response to induction therapy, were 1.6 times more likely to maintain clinical remission at week 52, according to data presented at Digestive Disease Week (DDW) 2023.1 Investigators emphasized that early remission was a strong predictor of favorable long-term outcomes in this patient population who were treated with advanced therapies. “Risk stratification to identify patients with high-risk IBD most likely to achieve long-term benefit with pharmacotherapy is needed,” wrote Babu Mohan, MBBS, associated with Gastroenterology and Hepatology at the University of Utah Health, and colleagues. “Early achievement of remission is a potentially favorable prognostic factor; however, the magnitude of benefit is unclear.” Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party ...

read more